Is Oklo a Millionaire Maker, or Is the Hype Overdone?

Oklo reported its first quarterly revenue of $1.21 million and achieved first criticality on its Groves test reactor, catalysts that drove shares up 14%. The small modular reactor developer now holds $3 billion in liquidity as it advances three business lines: compact nuclear reactors, fuel fabrication and recycling, and isotope production.

The company remains pre-commercial, and its valuation has climbed above 1,700 times sales—a ratio that reflects significant investor optimism around its long-term potential but also exposes the stock to volatility as milestones are either met or missed. The first criticality milestone on the Groves reactor marks tangible progress, yet substantial commercialization hurdles remain before revenue ramps meaningfully.

With the stock now pricing in aggressive growth assumptions, near-term execution will determine whether the recent surge holds or reverses. The company's cash position provides runway, but the path from experimental reactors to scaled deployment in a regulated industry is uncertain.